Terremoto Biosciences has secured $108 million in a Series C funding round, marking a significant follow-on investment. The capital will fuel the advancement of its pipeline of highly targeted small molecule medicines. Key investors participating in this round include RA Capital Management, Deep Track Capital, Osage University Partners, BeOne Medicines, OrbiMed, Third Rock Ventures, Novo Holdings, and Cormorant Asset Management.
Amount: $108.0M
